330 related articles for article (PubMed ID: 20419128)
1. Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.
Lahat G; Zhu QS; Huang KL; Wang S; Bolshakov S; Liu J; Torres K; Langley RR; Lazar AJ; Hung MC; Lev D
PLoS One; 2010 Apr; 5(4):e10105. PubMed ID: 20419128
[TBL] [Abstract][Full Text] [Related]
2. Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors.
Lee J; Hahm ER; Marcus AI; Singh SV
Mol Carcinog; 2015 Jun; 54(6):417-29. PubMed ID: 24293234
[TBL] [Abstract][Full Text] [Related]
3. Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells.
Suman S; Das TP; Sirimulla S; Alatassi H; Ankem MK; Damodaran C
Oncotarget; 2016 Mar; 7(12):13854-64. PubMed ID: 26883103
[TBL] [Abstract][Full Text] [Related]
4. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation.
Thaiparambil JT; Bender L; Ganesh T; Kline E; Patel P; Liu Y; Tighiouart M; Vertino PM; Harvey RD; Garcia A; Marcus AI
Int J Cancer; 2011 Dec; 129(11):2744-55. PubMed ID: 21538350
[TBL] [Abstract][Full Text] [Related]
5. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo.
Wang S; Ren W; Liu J; Lahat G; Torres K; Lopez G; Lazar AJ; Hayes-Jordan A; Liu K; Bankson J; Hazle JD; Lev D
Clin Cancer Res; 2010 May; 16(9):2591-604. PubMed ID: 20406839
[TBL] [Abstract][Full Text] [Related]
6. ML327 induces apoptosis and sensitizes Ewing sarcoma cells to TNF-related apoptosis-inducing ligand.
Rellinger EJ; Padmanabhan C; Qiao J; Appert A; Waterson AG; Lindsley CW; Beauchamp RD; Chung DH
Biochem Biophys Res Commun; 2017 Sep; 491(2):463-468. PubMed ID: 28716733
[TBL] [Abstract][Full Text] [Related]
7. The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin.
Bargagna-Mohan P; Hamza A; Kim YE; Khuan Abby Ho Y; Mor-Vaknin N; Wendschlag N; Liu J; Evans RM; Markovitz DM; Zhan CG; Kim KB; Mohan R
Chem Biol; 2007 Jun; 14(6):623-34. PubMed ID: 17584610
[TBL] [Abstract][Full Text] [Related]
8. Withaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivo.
Yang H; Wang Y; Cheryan VT; Wu W; Cui CQ; Polin LA; Pass HI; Dou QP; Rishi AK; Wali A
PLoS One; 2012; 7(8):e41214. PubMed ID: 22912669
[TBL] [Abstract][Full Text] [Related]
9. Withania somnifera root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition.
Yang Z; Garcia A; Xu S; Powell DR; Vertino PM; Singh S; Marcus AI
PLoS One; 2013; 8(9):e75069. PubMed ID: 24069380
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts.
Cornillie J; Wozniak A; Van Renterghem B; Van Winkel N; Wellens J; Gebreyohannes YK; Debiec-Rychter M; Sciot R; Hompes D; Schöffski P
BMC Cancer; 2019 Jul; 19(1):724. PubMed ID: 31331295
[TBL] [Abstract][Full Text] [Related]
11. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
12. Withaferin A is a potent inhibitor of angiogenesis.
Mohan R; Hammers HJ; Bargagna-Mohan P; Zhan XH; Herbstritt CJ; Ruiz A; Zhang L; Hanson AD; Conner BP; Rougas J; Pribluda VS
Angiogenesis; 2004; 7(2):115-22. PubMed ID: 15516832
[TBL] [Abstract][Full Text] [Related]
13. Withaferin a alters intermediate filament organization, cell shape and behavior.
Grin B; Mahammad S; Wedig T; Cleland MM; Tsai L; Herrmann H; Goldman RD
PLoS One; 2012; 7(6):e39065. PubMed ID: 22720028
[TBL] [Abstract][Full Text] [Related]
14. Withaferin-A--A Natural Anticancer Agent with Pleitropic Mechanisms of Action.
Lee IC; Choi BY
Int J Mol Sci; 2016 Mar; 17(3):290. PubMed ID: 26959007
[TBL] [Abstract][Full Text] [Related]
15. The Therapeutic Effects of Withaferin A against Cancer: Overview and Updates.
Abeesh P; Guruvayoorappan C
Curr Mol Med; 2024; 24(4):404-418. PubMed ID: 37076466
[TBL] [Abstract][Full Text] [Related]
16. Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line.
Makol A; Kaur H; Sharma S; Kanthaje S; Kaur R; Chakraborti A
Clin Mol Hepatol; 2020 Jan; 26(1):45-53. PubMed ID: 31564085
[TBL] [Abstract][Full Text] [Related]
17. Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells.
Choi MJ; Park EJ; Min KJ; Park JW; Kwon TK
Toxicol In Vitro; 2011 Apr; 25(3):692-8. PubMed ID: 21266191
[TBL] [Abstract][Full Text] [Related]
18. Dual-color imaging of angiogenesis and its inhibition in bone and soft tissue sarcoma.
Hayashi K; Yamauchi K; Yamamoto N; Tsuchiya H; Tomita K; Amoh Y; Hoffman RM; Bouvet M
J Surg Res; 2007 Jun; 140(2):165-70. PubMed ID: 17418866
[TBL] [Abstract][Full Text] [Related]
19. MS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivo.
Srivastava RK; Kurzrock R; Shankar S
Mol Cancer Ther; 2010 Dec; 9(12):3254-66. PubMed ID: 21041383
[TBL] [Abstract][Full Text] [Related]
20. Corneal antifibrotic switch identified in genetic and pharmacological deficiency of vimentin.
Bargagna-Mohan P; Paranthan RR; Hamza A; Zhan CG; Lee DM; Kim KB; Lau DL; Srinivasan C; Nakayama K; Nakayama KI; Herrmann H; Mohan R
J Biol Chem; 2012 Jan; 287(2):989-1006. PubMed ID: 22117063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
